Article info
PDFOvarian Cancer
The Role of HE4, a Novel Biomarker, in Predicting Optimal Cytoreduction After Neoadjuvant Chemotherapy in Advanced Ovarian Cancer
- Address correspondence and reprint requests to Stella Capriglione, MD, Department of Obstetrics and Gynecology, Campus Bio-Medico University of Rome, Via Alvaro del Portillo, 200-00128 Rome, Italy. E-mail: s.capriglione{at}unicampus.it.
Citation
The Role of HE4, a Novel Biomarker, in Predicting Optimal Cytoreduction After Neoadjuvant Chemotherapy in Advanced Ovarian Cancer
Publication history
- Received October 20, 2016
- Accepted November 23, 2016
- First published May 1, 2017.
Online issue publication
May 01, 2017
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2017 by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology.